NCT06539338View on ClinicalTrials.gov

Safety of INT2104 in Participants Aged 18 Years and Older Who Have B-cell Cancer That Came Back After Prior Treatment

PHASE1RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 7, 2024

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2031

Conditions
Lymphomas Non-Hodgkin's B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Interventions
GENETIC

INT2104

INT2104 is a lentiviral vector delivering a transgene for a chimeric antigen receptor specific for CD20 (CAR20)

Trial Locations (2)

Unknown

RECRUITING

Peter MacCallum Cancer Centre, Melbourne

RECRUITING

Westmead Hospital, Westmead

Sponsors
All Listed Sponsors
lead

Interius BioTherapeutics Inc.

INDUSTRY